Loading clinical trials...
Loading clinical trials...
Phase 2, Double-Blind, Randomized, Active-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of SAR447537 (INBRX-101) Compared to Plasma-Derived Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Conditions
Interventions
SAR447537
Zemaira
Locations
65
United States
University of Alabama at Birmingham- Site Number : 105
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
St Joseph's Hospital and Medical Center- Site Number : 126
Phoenix, Arizona, United States
St Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
David Geffen School of Medicine- Site Number : 124
Los Angeles, California, United States
David Geffen School of Medicine
Los Angeles, California, United States
Start Date
October 12, 2023
Primary Completion Date
August 6, 2025
Completion Date
August 6, 2025
Last Updated
August 11, 2025
NCT06389877
NCT06996756
NCT06891755
NCT03500731
NCT07059637
NCT07152834
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions